Goserelin is a synthetic long-acting agonist of the GONADOTROPIN-RELEASING HORMONE and is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer. Goserelin is a parenterally administered, gonadotropin-releasing hormone (GnRH) agonist which causes an inhibition of estrogen and androgen production and is used predominantly to treat prostate cancer. Goserelin has been associated with a modest rate of serum enzyme elevations during therapy but has not been convincingly linked to instances of clinically apparent acute liver injury.
Goserelin is a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin-releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females). Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. (NCI04)
Goserelin Acetate is the acetate salt of a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH). Continuous, prolonged administration of goserelin in males results in inhibition of pituitary gonadotropin secretion, leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
Mechanism of Action
Goserelin is a synthetic decapeptide analog of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in a biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.
Zoladex is a synthetic decapeptide analog of LHRH. Zoladex acts as a potent inhibitor of pituitary gonadotropin secretion when administered in a biodegradable formulation. Following initial administration, ZOLADEX causes an initial increase in serum-luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels with subsequent increases in serum levels of testosterone. Chronic administration of Zoladex leads to sustained suppression of pituitary gonadotropins, and serum levels of testosterone consequently fall into the range normally seen in surgically castrated men approximately 21 days after initiation of therapy. This leads to accessory sex organ regression. In animal and in in vitro studies, administration of goserelin resulted in the regression or inhibition of growth of the hormonally sensitive dimethylbenzanthracene (DMBA)-induced rat mammary tumor and Dunning R3327 prostate tumor. In clinical trials using Zoladex 3.6 mg with follow-up of more than 2 years, suppression of serum testosterone to castrate levels has been maintained for the duration of therapy.
Indications
- Goserelin is indicated for: – Use in combination with flutamide for the management of locally confined carcinoma of the prostate – Palliative treatment of advanced carcinoma of the prostate – The management of endometriosis – Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding – Use in the palliative treatment of advanced breast cancer in pre-and perimenopausal women
- Goserelin is a parenterally administered, gonadotropin-releasing hormone (GnRH) agonist which causes an inhibition of estrogen and androgen production and is used predominantly to treat prostate cancer.
- Use in combination with flutamide for the management of locally confined carcinoma of the prostate
- Palliative treatment of advanced carcinoma of the prostate
- The management of endometriosis
- Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding
- Use in the palliative treatment of advanced breast cancer in pre-and perimenopausal women
- Abnormal Uterine Bleeding
- Advanced Breast Cancer
- Endometriosis
- Advanced carcinoma of the prostate
- Stage T2b carcinoma of the prostate
- Stage T4 carcinoma of the prostate
- Goserelin is a medication that is used to suppress the production of sex hormones (testosterone and estrogen), particularly in the treatment of breast and prostate cancer. It is an injectable gonadotropin-releasing hormone agonist (GnRH agonist).
- Goserelin acetate is used for the palliative treatment of advanced prostate cancer. Therapy with a GnRH agonist (e.g., goserelin) currently is considered one of several first-line options for hormonal therapy in patients with prostate cancer
- Goserelin is used for the palliative treatment of endometriosis. The manufacturer states that experience with goserelin in the management of this condition has been limited to women 18 years of age and older who received consecutive therapy … with the drug for 6 months. Goserelin, like other GnRH analogs, produces a reversible hypoestrogenic state, which is thought to be principally responsible for the beneficial effects observed in endometriosis. A 6-month course of goserelin therapy can provide symptomatic (e.g., pain) relief and a reduction in endometriotic lesions; some degree of improvement has persisted in many patients for at least 6 months following completion of therapy. Substantial improvement of clinical symptoms usually occurs within 4 weeks of initiation of goserelin therapy.
- Goserelin is used in the palliative treatment of advanced breast cancer in premenopausal and perimenopausal women. In a multicenter, randomized, controlled clinical trial in women with estrogen- or progesterone-receptor-positive breast cancer, goserelin therapy or oophorectomy was associated with objective response rates (complete or partial responses) of 22-31 or 12-27%, time to treatment failure of 6-6.7 or 4-5.5 months, and median survival time of 33.2 or 33.6 months, respectively. In addition, subjective response, characterized by relief of pain and improved performance status, was reported in 48 or 50% of women receiving goserelin or undergoing surgery, respectively.
- Goserelin is used as an endometrial-thinning agent prior to endometrial ablation procedures for the treatment of dysfunctional uterine bleeding. In women with dysfunctional uterine bleeding, administration of goserelin (two doses of goserelin (3.6 mg each) given 4 weeks apart) prior to surgery suppressed endometrial growth, reduced uterine size and endometrial thickness, and facilitated surgical ablation.
Use in Cancer
Goserelin acetate is approved to treat:
- Breast cancer is advanced. It is used as palliative treatment in premenopausal and perimenopausal women.
- Prostate cancer. It is used with flutamide and radiation therapy in localized prostate cancer. It is also used as palliative treatment in advanced prostate cancer.
Goserelin acetate is also being studied in conditions related to cancer.
Contraindications
- Goserelin is contraindicated in patients with hypersensitivity to goserelin, GnRH, or with Gonadotropin-Releasing Hormone (GnRH) Analogs hypersensitivity; anaphylactic reactions to synthetic GnRH or GnRH agonist analogs have been reported.
- cancer metastasis to bone
- diabetes
- high cholesterol
- low amount of magnesium in the blood
- low amount of calcium in the blood
- high amount of calcium in the blood
- low amount of potassium in the blood
- overweight
- high blood pressure
- a heart attack
- prolonged QT interval on EKG
- chronic heart failure
- abnormal EKG with QT changes from birth
- a stroke
- pregnancy
- obstruction of any part of the urinary tract
- tobacco smoking
Dosage
Prostate Cancer
For the palliative treatment of advanced carcinoma of the prostate:
- 3.6 mg or 10.8 mg subcutaneously into the upper abdominal wall once
- The 3.6 mg dosage may be repeated every 28 days.
- The 10.8 mg dosage may be repeated every 12 weeks.
- Intended for long-term administration unless clinically inappropriate.
- Prostate cancer, stage B2 to C (in combination with an antiandrogen and radiotherapy; begin 8 weeks prior to radiotherapy): Males: SubQ:
- Combination 28-day/12-week implant: 3.6 mg implant, followed in 28 days by 10.8 mg implant
OR
- 28-day implant (alternate dosing): 3.6 mg; repeated every 28 days for a total of 4 doses (2 depots preceding and 2 during radiotherapy)
- In combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment should start 8 weeks prior to radiation therapy and continue during radiation.
- For the palliative treatment of advanced carcinoma of the prostate.
Endometriosis
- 3.6 mg subcutaneously into the upper abdominal wall once; repeat every 28 days. The recommended duration of therapy is 6 months.
- For the management of endometriosis, including pain relief and reduction of endometriotic lesions.
Breast Cancer–Palliative
- For use in the palliative treatment of advanced breast cancer: 3.6 mg subcutaneously into the upper abdominal wall once; repeat every 28 days
- Intended for long-term administration unless clinically inappropriate.
- For the palliative treatment of advanced breast cancer in pre-and perimenopausal women
Dose for Bleeding
- 1 or 2 of the 3.6 mg subcutaneous depot injections (with each depot given 4 weeks apart). When 1 depot is administered, surgery should be performed at 4 weeks.
- When 2 depots are administered, surgery should be performed within 2 to 4 weeks following the administration of the second depot.
Administration Technique
The proper method of administration of ZOLADEX is described in the instructions that follow.
- Put the patient in a comfortable position with the upper part of the body slightly raised. Prepare an area of the anterior abdominal wall below the navel line with an alcohol swab.
NOTE: Caution should be taken while injecting ZOLADEX into the anterior abdominal wall due to the proximity of the underlying inferior epigastric artery and its branches. - Examine the foil pouch and syringe for damage. Remove the syringe from the opened foil pouch and hold the syringe at a slight angle to the light. Check that at least part of the ZOLADEX implant is visible.
- Grasp the red plastic safety tab and pull away from the syringe, and discard. Remove the needle cover. Unlike liquid injections, there is no need to remove air bubbles as attempts to do so may displace the ZOLADEX implant.
- Holding the syringe around the protective sleeve, using an aseptic technique, pinch the skin of the patient’s anterior abdominal wall below the navel line. With the bevel of the needle facing up, insert the needle at a 30 to 45-degree angle to the skin in one continuous deliberate motion until the protective sleeve touches the patient’s skin.
NOTE: The ZOLADEX syringe cannot be used for aspiration. If the hypodermic needle penetrates a large vessel, blood will be seen instantly in the syringe chamber. If a vessel is penetrated, withdraw the needle and inject it with a new syringe elsewhere. Monitor patients for signs or symptoms of abdominal hemorrhage. Use extra care when administering ZOLADEX to patients with a low BMI and/or to patients receiving full-dose anticoagulation. - Do not penetrate into muscle or peritoneum.
- To administer the ZOLADEX implant and to activate the protective sleeve, grasp the barrel at the finger grip and depress the plunger until you cannot depress it any further. If the plunger is not depressed fully, the protective sleeve will NOT activate. When the protective sleeve ‘clicks’, the protective sleeve will automatically begin to slide to cover the needle.
NOTE: The needle does not retract. - Withdraw the needle and allow the protective sleeve to slide and cover the needle. Dispose of the syringe in an approved sharps collector.
Side Effects
The Most Common
- headache
- hot flashes (a sudden wave of mild or intense body heat)
- sweating
- sudden reddening of the face, neck, or upper chest
- lack of energy
- loss of appetite
- breast pain or change in breast size in women
- decreased sexual desire or ability
- painful sexual intercourse
- vaginal discharge, dryness, or itching
- menstruation (periods)
- swelling of the hands, feet, ankles, or lower legs
- depression
- nervousness
- unable to control emotions and frequent mood changes
- difficulty falling asleep or staying asleep
- pain, itching, swelling, or redness at the place where the implant was inserted
- hives
- rash
- itching
- difficulty breathing or swallowing
- chest pain
- pain in the arms, back, neck, or jaw
- unusual weight gain
- slow or difficult speech
- dizziness or fainting
- weakness or numbness of an arm or leg
- bone pain
- not able to move legs
- painful or difficult urination
- frequent urination
- extreme thirst
- weakness
- blurred vision
- dry mouth
- nausea
- vomiting
- breath that smells fruity
- decreased consciousness
More Common
- Fast or irregular heartbeat
- Bone, muscle, or joint pain
- changes in the skin color of the face
- fainting
- fast or irregular breathing
- numbness or tingling of the hands or feet
- puffiness or swelling of the eyelids or around the eyes
- skin rash, hives, or itching
- sudden, severe decrease in blood pressure and collapse
- tightness in the chest
- troubled breathing
- pain, bruising, swelling, redness, oozing, or bleeding where the implant was injected;
- dizziness, trouble breathing, feeling light-headed (like you might pass out);
- high blood sugar – increased thirst, increased urination, dry mouth, fruity breath odor;
- high calcium levels – confusion, tiredness, nausea, vomiting, loss of appetite, constipation, increased thirst or urination, weight loss;
- heart attack symptoms – chest pain or pressure, pain spreading to your jaw or shoulder, nausea, sweating; or
- signs of a blood clot – sudden numbness or weakness on one side of the body, chest pain, problems with vision or speech, pain or swelling in one leg.
RARE
- Anxiety
- deepening of voice
- increased hair growth
- mental depression
- mood changes
- Pain in the chest
- pain in the groin or legs (especially in the calves of the legs)
- Sudden sweating and feelings of warmth (also called hot flashes)
- Blurred vision
- burning, itching, redness, or swelling at the place of injection
- decreased interest in sexual intercourse
- dizziness
- headache
- nausea or vomiting
- swelling and increased tenderness of the breasts
- swelling of the feet or lower legs
- trouble sleeping
- weight gain
- Light, irregular vaginal bleeding
- stopping of menstrual periods
- Burning, dryness, or itching of the vagina
- pelvic pain
- Bone pain
- constipation
- decreased size of the testicles
- inability to have or keep an erection
Drug Interactions
Abacavir | Goserelin may decrease the excretion rate of Abacavir which could result in a higher serum level. |
Acarbose | The therapeutic efficacy of Acarbose can be decreased when used in combination with Goserelin. |
Aceclofenac | Aceclofenac may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Acemetacin | Acemetacin may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Acetaminophen | Goserelin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. |
Acetazolamide | Acetazolamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Acetohexamide | The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Goserelin. |
Acetylsalicylic acid | Acetylsalicylic acid may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Aclidinium | Goserelin may decrease the excretion rate of Aclidinium which could result in a higher serum level. |
Acrivastine | The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Goserelin. |
Acyclovir | Acyclovir may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Adefovir dipivoxil | Adefovir dipivoxil may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Adenosine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Adenosine. |
Ajmaline | The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Goserelin. |
Albiglutide | The therapeutic efficacy of Albiglutide can be decreased when used in combination with Goserelin. |
Albutrepenonacog | Goserelin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level. |
Alclofenac | Alclofenac may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Aldesleukin | Goserelin may decrease the excretion rate of Aldesleukin which could result in a higher serum level. |
Alfuzosin | The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Goserelin. |
Alimemazine | The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Goserelin. |
Allopurinol | Goserelin may decrease the excretion rate of Allopurinol which could result in a higher serum level. |
Almasilate | Goserelin may decrease the excretion rate of Almasilate which could result in a higher serum level. |
Almotriptan | Goserelin may decrease the excretion rate of Almotriptan which could result in a higher serum level. |
Alogliptin | The therapeutic efficacy of Alogliptin can be decreased when used in combination with Goserelin. |
Alprazolam | Goserelin may decrease the excretion rate of Alprazolam which could result in a higher serum level. |
Amantadine | The risk or severity of QTc prolongation can be increased when Amantadine is combined with Goserelin. |
Amifampridine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Amifampridine. |
Amikacin | Goserelin may decrease the excretion rate of Amikacin which could result in a higher serum level. |
Amiloride | Amiloride may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Aminophenazone | Aminophenazone may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Amiodarone | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Amiodarone. |
Amisulpride | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Amisulpride. |
Amitriptyline | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Amitriptyline. |
Ammonium | Goserelin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level. |
Amodiaquine | The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Goserelin. |
Amoxapine | The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Goserelin. |
Amoxicillin | Goserelin may decrease the excretion rate of Amoxicillin which could result in a higher serum level. |
Amphetamine | Goserelin may decrease the excretion rate of Amphetamine which could result in a higher serum level. |
Amphotericin B | Amphotericin B may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Ampicillin | Goserelin may decrease the excretion rate of Ampicillin which could result in a higher serum level. |
Amrinone | Goserelin may decrease the excretion rate of Amrinone which could result in a higher serum level. |
Anagrelide | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Anagrelide. |
Ancestim | Goserelin may decrease the excretion rate of Ancestim which could result in a higher serum level. |
Antazoline | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Antazoline. |
Antihemophilic | Goserelin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level. |
Antipyrine | Antipyrine may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Antithrombin III | Goserelin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level. |
Antrafenine | Antrafenine may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Apalutamide | Goserelin may decrease the excretion rate of Apalutamide which could result in a higher serum level. |
Apomorphine | The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Goserelin. |
Apremilast | Goserelin may decrease the excretion rate of Apremilast which could result in a higher serum level. |
Arformoterol | The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Goserelin. |
Aripiprazole | The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Goserelin. |
Aripiprazole lauroxil | The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Goserelin. |
Arsenic trioxide | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Arsenic trioxide. |
Artemether | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Artemether. |
Articaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Articaine. |
Asenapine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Asenapine. |
Astemizole | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Astemizole. |
Atazanavir | The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Goserelin. |
Atomoxetine | The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Goserelin. |
Atropine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Atropine. |
Auranofin | Goserelin may decrease the excretion rate of Auranofin which could result in a higher serum level. |
Aurothioglucose | Goserelin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level. |
Azacitidine | Goserelin may decrease the excretion rate of Azacitidine which could result in a higher serum level. |
Azatadine | The risk or severity of QTc prolongation can be increased when Azatadine is combined with Goserelin. |
Azathioprine | Goserelin may decrease the excretion rate of Azathioprine which could result in a higher serum level. |
Azelaic acid | Goserelin may decrease the excretion rate of Azelaic acid which could result in a higher serum level. |
Azithromycin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Azithromycin. |
Aztreonam | Goserelin may decrease the excretion rate of Aztreonam which could result in a higher serum level. |
Bacitracin | Bacitracin may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Baclofen | Goserelin may decrease the excretion rate of Baclofen which could result in a higher serum level. |
Balsalazide | Balsalazide may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Baricitinib | Goserelin may decrease the excretion rate of Baricitinib which could result in a higher serum level. |
Bedaquiline | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Bedaquiline. |
Bendroflumethiaz | Bendroflumethiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Benorilate | Benorilate may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Benoxaprofen | Benoxaprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Benserazide | Goserelin may decrease the excretion rate of Benserazide which could result in a higher serum level. |
Benzatropine | The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Goserelin. |
Benznidazole | Goserelin may decrease the excretion rate of Benznidazole which could result in a higher serum level. |
Benzocaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Benzocaine. |
Benzthiazide | Benzthiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Benzydamine | Benzydamine may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Benzyl alcohol. |
Bepotastine | Goserelin may decrease the excretion rate of Bepotastine which could result in a higher serum level. |
Bepridil | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Bepridil. |
Berotralstat | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Berotralstat. |
Bicisate | Goserelin may decrease the excretion rate of Bicisate which could result in a higher serum level. |
Bilastine | The risk or severity of QTc prolongation can be increased when Bilastine is combined with Goserelin. |
Bismuth | Goserelin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level. |
Bisoprolol | Goserelin may decrease the excretion rate of Bisoprolol which could result in a higher serum level. |
Bisoxatin | Goserelin may decrease the excretion rate of Bisoxatin which could result in a higher serum level. |
Bleomycin | Goserelin may decrease the excretion rate of Bleomycin which could result in a higher serum level. |
Bortezomib | The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Goserelin. |
Bretylium | The risk or severity of QTc prolongation can be increased when Bretylium is combined with Goserelin. |
Brivaracetam | Goserelin may decrease the excretion rate of Brivaracetam which could result in a higher serum level. |
Bromazepam | Goserelin may decrease the excretion rate of Bromazepam which could result in a higher serum level. |
Bromocriptine | The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Goserelin. |
Bromotheophylline | Bromotheophylline may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Brompheniramine | The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Goserelin. |
Buclizine | The risk or severity of QTc prolongation can be increased when Buclizine is combined with Goserelin. |
Budesonide | Goserelin may decrease the excretion rate of Budesonide which could result in a higher serum level. |
Bumadizone | Bumadizone may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Bumetanide | Bumetanide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Bupivacaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Bupivacaine. |
Bupropion | Goserelin may decrease the excretion rate of Bupropion which could result in a higher serum level. |
Buserelin | The risk or severity of QTc prolongation can be increased when Buserelin is combined with Goserelin. |
Buspirone | Goserelin may decrease the excretion rate of Buspirone which could result in a higher serum level. |
Butabarbital | Goserelin may decrease the excretion rate of Butabarbital which could result in a higher serum level. |
Butacaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Butacaine. |
Butamben | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Butamben. |
Butriptyline | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Butriptyline. |
Canagliflozin | The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin. |
Canrenoic acid | Canrenoic acid may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Capecitabine | Goserelin may decrease the excretion rate of Capecitabine which could result in a higher serum level. |
Capreomycin | Goserelin may decrease the excretion rate of Capreomycin which could result in a higher serum level. |
Capromab | Goserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent. |
Capsaicin | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Capsaicin. |
Carbamazepine | Goserelin may decrease the excretion rate of Carbamazepine which could result in a higher serum level. |
Carbidopa | Goserelin may decrease the excretion rate of Carbidopa which could result in a higher serum level. |
Carbinoxamine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Carbinoxamine. |
Carboplatin | Carboplatin may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Carmustine | Goserelin may decrease the excretion rate of Carmustine which could result in a higher serum level. |
Carprofen | Carprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefaclor | Cefaclor may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefadroxil | Cefadroxil may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefalotin | Cefalotin may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefamandole | Cefamandole may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefapirin | Cefapirin may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefazolin | Cefazolin may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefdinir | Goserelin may decrease the excretion rate of Cefdinir which could result in a higher serum level. |
Cefditoren | Cefditoren may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefepime | Cefepime may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefmenoxime | Cefmenoxime may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefmetazole | Cefmetazole may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefonicid | Cefonicid may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefoperazone | Cefoperazone may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Ceforanide | Ceforanide may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefotaxime | Cefotaxime may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefotetan | Cefotetan may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefotiam | Cefotiam may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefoxitin | Cefoxitin may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefpiramide | Cefpiramide may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefpirome | Cefpirome may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefpodoxime | Cefpodoxime may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefprozil | Cefprozil may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefradine | Cefradine may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Ceftaroline | Ceftaroline fosamil may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Ceftazidime | Ceftazidime may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Ceftibuten | Ceftibuten may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Ceftizoxime | Ceftizoxime may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Ceftobiprole | Ceftobiprole may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Ceftolozane | Goserelin may decrease the excretion rate of Ceftolozane which could result in a higher serum level. |
Ceftriaxone | Ceftriaxone may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cefuroxime | Cefuroxime may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Celecoxib | Celecoxib may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Celiprolol | The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Goserelin. |
Cephalexin | Cephalexin may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cephaloglycin | Cephaloglycin may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Ceritinib | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ceritinib. |
Certolizumab pegol | Goserelin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level. |
Cetirizine | The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Goserelin. |
Cevimeline | Goserelin may decrease the excretion rate of Cevimeline which could result in a higher serum level. |
Chloral hydrate | Goserelin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level. |
Chlorcyclizine | The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Goserelin. |
Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Chloroprocaine. |
Chloroquine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Chloroquine. |
Chlorothiazide | Chlorothiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Chloroxylenol | Goserelin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level. |
Chlorpheniramine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Chlorpheniramine. |
Chlorpromazine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Chlorpromazine. |
Chlorpropamide | The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Goserelin. |
Chlorprothixene | The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Goserelin. |
Chlorthalidone | Chlorthalidone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Chlorzoxazone | Goserelin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level. |
Choline C 11 | Goserelin may decrease effectiveness of Choline C 11 as a diagnostic agent. |
Choline magnesium | Choline magnesium trisalicylate may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Choline salicylate | Goserelin may decrease the excretion rate of Choline salicylate which could result in a higher serum level. |
Chondroitin sulfate | Goserelin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level. |
Chromic chloride | Goserelin may decrease the excretion rate of Chromic chloride which could result in a higher serum level. |
Chromic nitrate | Goserelin may decrease the excretion rate of Chromic nitrate which could result in a higher serum level. |
Chromium | Goserelin may decrease the excretion rate of Chromium which could result in a higher serum level. |
Chromium | Goserelin may decrease the excretion rate of Chromium gluconate which could result in a higher serum level. |
Chromium nicotinate | Goserelin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level. |
Chromous sulfate | Goserelin may decrease the excretion rate of Chromous sulfate which could result in a higher serum level. |
Cidofovir | Cidofovir may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cilostazol | The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Goserelin. |
Cimetidine | Goserelin may decrease the excretion rate of Cimetidine which could result in a higher serum level. |
Cinchocaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Cinchocaine. |
Cinnarizine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Cinnarizine. |
Cinoxacin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Cinoxacin. |
Ciprofloxacin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ciprofloxacin. |
Cisapride | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Cisapride. |
Cisplatin | Goserelin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
Citalopram | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Citalopram. |
Clarithromycin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Clarithromycin. |
Clemastine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Clemastine. |
Clevidipine | Goserelin may decrease the excretion rate of Clevidipine which could result in a higher serum level. |
Clobazam | Goserelin may decrease the excretion rate of Clobazam which could result in a higher serum level. |
clofarabine | Goserelin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
Clofazimine | The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Goserelin. |
Clomipramine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Clomipramine. |
Clonazepam | Goserelin may decrease the excretion rate of Clonazepam which could result in a higher serum level. |
Clorazepic acid | Goserelin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level. |
Clove oil | Goserelin may decrease the excretion rate of Clove oil which could result in a higher serum level. |
Clozapine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Clozapine. |
Cocaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Cocaine. |
Colchicine | Goserelin may decrease the excretion rate of Colchicine which could result in a higher serum level. |
Colistimethate | Colistimethate may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Colistin | Goserelin may decrease the excretion rate of Colistin which could result in a higher serum level. |
Conivaptan | Conivaptan may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Conjugated | Goserelin may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. |
Corifollitropin | The therapeutic efficacy of Corifollitropin alfa can be increased when used in combination with Goserelin. |
Crizotinib | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Crizotinib. |
Cyanocobalamin | Goserelin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level. |
Cyclizine | The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Goserelin. |
Cyclopenthiazide | Cyclopenthiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Cyclosporine | Cyclosporine may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Cyclothiazide | Cyclothiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Cyproheptadine | The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Goserelin. |
Dabigatran | Goserelin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level. |
Dabrafenib | The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Goserelin. |
Dacarbazine | Goserelin may decrease the excretion rate of Dacarbazine which could result in a higher serum level. |
Dalfampridine | Goserelin may decrease the excretion rate of Dalfampridine which could result in a higher serum level. |
Dapagliflozin | The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Goserelin. |
Daptomycin | Goserelin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Goserelin. |
Dasatinib | The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Goserelin. |
Deferiprone | Goserelin may decrease the excretion rate of Deferiprone which could result in a higher serum level. |
Degarelix | The risk or severity of QTc prolongation can be increased when Degarelix is combined with Goserelin. |
Delafloxacin | The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Goserelin. |
Delamanid | Goserelin may increase the QTc-prolonging activities of Delamanid. |
Desflurane | The risk or severity of QTc prolongation can be increased when Desflurane is combined with Goserelin. |
Desipramine | The risk or severity of QTc prolongation can be increased when Desipramine is combined with Goserelin. |
Desloratadine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Desloratadine. |
Desmopressin | Goserelin may decrease the excretion rate of Desmopressin which could result in a higher serum level. |
Desvenlafaxine | Goserelin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level. |
Deutetrabenazine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Deutetrabenazine. |
Dexbrompheniramine | The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Goserelin. |
Dexchlorpheniramine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dexchlorpheniramine maleate. |
Dexibuprofen | Dexibuprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Dexketoprofen | Dexketoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Dexmedetomidine | Goserelin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level. |
Dexpanthenol | Goserelin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level. |
Dexrazoxane | Goserelin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
Dextran | Goserelin may decrease the excretion rate of Dextran which could result in a higher serum level. |
Diatrizoate | Goserelin may decrease the excretion rate of Diatrizoate which could result in a higher serum level. |
Diazepam | Goserelin may decrease the excretion rate of Diazepam which could result in a higher serum level. |
Dichlorobenzyl | Goserelin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level. |
Diclofenac | Diclofenac may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Diclofenamide | Diclofenamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Dicyclomine | Goserelin may decrease the excretion rate of Dicyclomine which could result in a higher serum level. |
Didanosine | Goserelin may decrease the excretion rate of Didanosine which could result in a higher serum level. |
Dienogest | Goserelin may decrease the excretion rate of Dienogest which could result in a higher serum level. |
Diflunisal | Diflunisal may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Difluocortolone | Goserelin may decrease the excretion rate of Difluocortolone which could result in a higher serum level. |
Digitoxin | The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Goserelin. |
Digoxin | Goserelin may decrease the excretion rate of Digoxin which could result in a higher serum level. |
Dihydrostreptomycin | Dihydrostreptomycin may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Diltiazem | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Diltiazem. |
Dimenhydrinate | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dimenhydrinate. |
Dimercaprol | Goserelin may decrease the excretion rate of Dimercaprol which could result in a higher serum level. |
Dimethyl sulfoxide | Goserelin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level. |
Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Diphenhydramine. |
Disopyramide | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Disopyramide. |
Disulfiram | The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Goserelin. |
DL-Methylephedrine | Goserelin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level. |
Dobutamine | Goserelin may decrease the excretion rate of Dobutamine which could result in a higher serum level. |
Dofetilide | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dofetilide. |
Dolasetron | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dolasetron. |
Domperidone | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Domperidone. |
Dopamine | Goserelin may decrease the excretion rate of Dopamine which could result in a higher serum level. |
Doripenem | Goserelin may decrease the excretion rate of Doripenem which could result in a higher serum level. |
Dosulepin | The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Goserelin. |
Doxacurium | Goserelin may decrease the excretion rate of Doxacurium which could result in a higher serum level. |
Doxepin | The risk or severity of QTc prolongation can be increased when Doxepin is combined with Goserelin. |
Doxycycline | Goserelin may decrease the excretion rate of Doxycycline which could result in a higher serum level. |
Doxylamine | The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Goserelin. |
Dronedarone | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dronedarone. |
Droperidol | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Droperidol. |
Drospirenone | Drospirenone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Droxidopa | Goserelin may decrease the excretion rate of Droxidopa which could result in a higher serum level. |
Dulaglutide | The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Goserelin. |
Duloxetine | Goserelin may decrease the excretion rate of Duloxetine which could result in a higher serum level. |
Dyclonine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Dyclonine. |
Dyphylline | Goserelin may decrease the excretion rate of Dyphylline which could result in a higher serum level. |
Ebastine | The risk or severity of QTc prolongation can be increased when Ebastine is combined with Goserelin. |
Edoxaban | Goserelin may decrease the excretion rate of Edoxaban which could result in a higher serum level. |
Edrophonium | Goserelin may decrease the excretion rate of Edrophonium which could result in a higher serum level. |
Efavirenz | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Efavirenz. |
Eliglustat | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Eliglustat. |
Emedastine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Emedastine. |
Empagliflozin | The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Goserelin. |
Enalaprilat | Goserelin may decrease the excretion rate of Enalaprilat which could result in a higher serum level. |
Encainide | The risk or severity of QTc prolongation can be increased when Encainide is combined with Goserelin. |
Encorafenib | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Encorafenib. |
Enoxacin | The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Goserelin. |
Entrectinib | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Entrectinib. |
Enzalutamide | Goserelin may decrease the excretion rate of Enzalutamide which could result in a higher serum level. |
Epinastine | The risk or severity of QTc prolongation can be increased when Epinastine is combined with Goserelin. |
Eplerenone | Eplerenone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Epoprostenol | Goserelin may decrease the excretion rate of Epoprostenol which could result in a higher serum level. |
Eribulin | The risk or severity of QTc prolongation can be increased when Eribulin is combined with Goserelin. |
Erlotinib | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Erlotinib. |
Ertapenem | Goserelin may decrease the excretion rate of Ertapenem which could result in a higher serum level. |
Ertugliflozin | The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Goserelin. |
Erythromycin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Erythromycin. |
Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Goserelin. |
Escitalopram | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Escitalopram. |
Esmolol | The risk or severity of QTc prolongation can be increased when Esmolol is combined with Goserelin. |
Estazolam | Goserelin may decrease the excretion rate of Estazolam which could result in a higher serum level. |
Estradiol | Goserelin may decrease the excretion rate of Estradiol which could result in a higher serum level. |
Estradiol acetate | Goserelin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level. |
Estradiol cypionate | Goserelin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level. |
Estradiol dienanthate | Goserelin may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level. |
Estradiol valerate | Goserelin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level. |
Estrone sulfate | Goserelin may decrease the excretion rate of Estrone sulfate which could result in a higher serum level. |
Eszopiclone | Goserelin may decrease the excretion rate of Eszopiclone which could result in a higher serum level. |
Etacrynic acid | Etacrynic acid may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Etafedrine | Goserelin may decrease the excretion rate of Etafedrine which could result in a higher serum level. |
Ethambutol | Goserelin may decrease the excretion rate of Ethambutol which could result in a higher serum level. |
Ethosuximide | The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Goserelin. |
Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Ethyl chloride. |
Etidocaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Etidocaine. |
Etodolac | Etodolac may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Etomidate | Goserelin may decrease the excretion rate of Etomidate which could result in a higher serum level. |
Etonogestrel | Goserelin may decrease the excretion rate of Etonogestrel which could result in a higher serum level. |
Etoricoxib | Etoricoxib may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Eucalyptus oil | Goserelin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level. |
Exenatide | The therapeutic efficacy of Exenatide can be decreased when used in combination with Goserelin. |
Ezogabine | The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Goserelin. |
Famotidine | The risk or severity of QTc prolongation can be increased when Famotidine is combined with Goserelin. |
Felbamate | The risk or severity of QTc prolongation can be increased when Felbamate is combined with Goserelin. |
Felodipine | The risk or severity of QTc prolongation can be increased when Felodipine is combined with Goserelin. |
Fenbufen | Fenbufen may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Fenofibrate | Goserelin may decrease the excretion rate of Fenofibrate which could result in a higher serum level. |
Fenofibric acid | Goserelin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level. |
Fenoldopam | Goserelin may decrease the excretion rate of Fenoldopam which could result in a higher serum level. |
Fenoprofen | Fenoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Fentanyl | Goserelin may decrease the excretion rate of Fentanyl which could result in a higher serum level. |
Fesoterodine | Goserelin may decrease the excretion rate of Fesoterodine which could result in a higher serum level. |
Fexinidazole | The risk or severity of adverse effects can be increased when Goserelin is combined with Fexinidazole. |
Finerenone | Finerenone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Flavoxate | Goserelin may decrease the excretion rate of Flavoxate which could result in a higher serum level. |
Flecainide | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Flecainide. |
Floctafenine | Floctafenine may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Florbetaben (18F) | Goserelin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level. |
Florbetapir (18F) | Goserelin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level. |
Floxuridine | Goserelin may decrease the excretion rate of Floxuridine which could result in a higher serum level. |
Fluconazole | The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Goserelin. |
Flucytosine | Goserelin may decrease the excretion rate of Flucytosine which could result in a higher serum level. |
Fludeoxyglucose | Goserelin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level. |
Flumazenil | Goserelin may decrease the excretion rate of Flumazenil which could result in a higher serum level. |
Fluocinolone | Goserelin may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level. |
Fluorouracil | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Fluorouracil. |
Fluoxetine | The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Goserelin. |
Flupentixol | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Flupentixol. |
Flurazepam | Goserelin may decrease the excretion rate of Flurazepam which could result in a higher serum level. |
Flurbiprofen | Flurbiprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Fluspirilene | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Fluspirilene. |
Flutamide | Goserelin may decrease the excretion rate of Flutamide which could result in a higher serum level. |
Fluvoxamine | Goserelin may decrease the excretion rate of Fluvoxamine which could result in a higher serum level. |
Folic acid | Goserelin may decrease the excretion rate of Folic acid which could result in a higher serum level. |
Fomepizole | Goserelin may decrease the excretion rate of Fomepizole which could result in a higher serum level. |
Fondaparinux | Goserelin may decrease the excretion rate of Fondaparinux which could result in a higher serum level. |
Formestane | Goserelin may decrease the excretion rate of Formestane which could result in a higher serum level. |
Formoterol | The risk or severity of QTc prolongation can be increased when Formoterol is combined with Goserelin. |
Foscarnet | The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Goserelin. |
Fosfomycin | Goserelin may decrease the excretion rate of Fosfomycin which could result in a higher serum level. |
Fosinopril | Goserelin may decrease the excretion rate of Fosinopril which could result in a higher serum level. |
Fostemsavir | The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Goserelin. |
Framycetin | Framycetin may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Furosemide | Furosemide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Gabapentin | Goserelin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level. |
Gadobenic acid | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Gadobenic acid. |
Gadodiamide | Goserelin may decrease the excretion rate of Gadodiamide which could result in a higher serum level. |
Gadofosveset | Goserelin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level. |
Gadopentetic acid | Goserelin may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level. |
Gadoteric acid | Goserelin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level. |
Gadoteridol | Goserelin may decrease the excretion rate of Gadoteridol which could result in a higher serum level. |
Galantamine | The risk or severity of QTc prolongation can be increased when Galantamine is combined with Goserelin. |
Ganciclovir | Goserelin may decrease the excretion rate of Ganciclovir which could result in a higher serum level. |
Gatifloxacin | The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Goserelin. |
Gemcitabine | Goserelin may decrease the excretion rate of Gemcitabine which could result in a higher serum level. |
Gemfibrozil | Goserelin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level. |
Gemifloxacin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Gemifloxacin. |
Gentamicin | Goserelin may decrease the excretion rate of Gentamicin which could result in a higher serum level. |
Gilteritinib | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Gilteritinib. |
Gimeracil | Goserelin may decrease the excretion rate of Gimeracil which could result in a higher serum level. |
Givosiran | Givosiran may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Glasdegib | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Glasdegib. |
Gliclazide | The therapeutic efficacy of Gliclazide can be decreased when used in combination with Goserelin. |
Glimepiride | The therapeutic efficacy of Glimepiride can be decreased when used in combination with Goserelin. |
Glipizide | The therapeutic efficacy of Glipizide can be decreased when used in combination with Goserelin. |
Gliquidone | The therapeutic efficacy of Gliquidone can be decreased when used in combination with Goserelin. |
Glyburide | The therapeutic efficacy of Glyburide can be decreased when used in combination with Goserelin. |
Glycerol phenylbu | Goserelin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level. |
Glymidine | The therapeutic efficacy of Glymidine can be decreased when used in combination with Goserelin. |
Golodirsen | Goserelin may decrease the excretion rate of Golodirsen which could result in a higher serum level. |
Granisetron | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Granisetron. |
Grepafloxacin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Grepafloxacin. |
Guanethidine | Goserelin may decrease the excretion rate of Guanethidine which could result in a higher serum level. |
Guanfacine | Goserelin may decrease the excretion rate of Guanfacine which could result in a higher serum level. |
Halofantrine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Halofantrine. |
Haloperidol | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Haloperidol. |
Histrelin | The risk or severity of QTc prolongation can be increased when Histrelin is combined with Goserelin. |
Hydralazine | Goserelin may decrease the excretion rate of Hydralazine which could result in a higher serum level. |
Hydrochlorothiazide | Hydrochlorothiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Hydroflumethiazide | Hydroflumethiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Hydromorphone | Goserelin may decrease the excretion rate of Hydromorphone which could result in a higher serum level. |
Hydroxocobalamin | Goserelin may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level. |
Hydroxychloroquine | The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Goserelin. |
Hydroxyethyl Starch | Goserelin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level. |
Hydroxyzine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Hydroxyzine. |
Hyoscyamine | The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Goserelin. |
Ibandronate | The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Goserelin. |
Ibuprofen | Ibuprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Ibutilide | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ibutilide. |
Icatibant | Goserelin may decrease the excretion rate of Icatibant which could result in a higher serum level. |
Icosapent | Icosapent may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Idarucizumab | Goserelin may decrease the excretion rate of Idarucizumab which could result in a higher serum level. |
Idebenone | Goserelin may decrease the excretion rate of Idebenone which could result in a higher serum level. |
Ifosfamide | Goserelin may decrease the excretion rate of Ifosfamide which could result in a higher serum level. |
Iloperidone | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Iloperidone. |
Imatinib | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Imatinib. |
Imipramine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Imipramine. |
Indacaterol | The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Goserelin. |
Indapamide | Indapamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Indigotindisulfonic | Goserelin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level. |
Indomethacin | Indomethacin may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Inosine pranobex | Goserelin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level. |
Inositol | Goserelin may decrease the excretion rate of Inositol which could result in a higher serum level. |
Inotersen | The risk or severity of QTc prolongation can be increased when Inotersen is combined with Goserelin. |
Insulin aspart | The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Goserelin. |
Insulin beef | The therapeutic efficacy of Insulin beef can be decreased when used in combination with Goserelin. |
Insulin degludec | The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Goserelin. |
Insulin detemir | The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Goserelin. |
Insulin glargine | The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Goserelin. |
Insulin glulisine | The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Goserelin. |
Insulin human | The therapeutic efficacy of Insulin human can be decreased when used in combination with Goserelin. |
Insulin lispro | The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Goserelin. |
Insulin pork | The therapeutic efficacy of Insulin pork can be decreased when used in combination with Goserelin. |
Iobenguane | Goserelin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level. |
Iodixanol | Goserelin may decrease the excretion rate of Iodixanol which could result in a higher serum level. |
Ioflupane I-123 | Goserelin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level. |
Iopromide | Goserelin may decrease the excretion rate of Iopromide which could result in a higher serum level. |
Iothalamic acid | Goserelin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level. |
Ioversol | Goserelin may decrease the excretion rate of Ioversol which could result in a higher serum level. |
Ioxilan | Goserelin may decrease the excretion rate of Ioxilan which could result in a higher serum level. |
Ipecac | Goserelin may decrease the excretion rate of Ipecac which could result in a higher serum level. |
Ipilimumab | Goserelin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. |
Isoflurane | The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Goserelin. |
Isoniazid | Goserelin may decrease the excretion rate of Isoniazid which could result in a higher serum level. |
Isosorbide | Isosorbide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Isosorbide | Goserelin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level. |
Isosulfan blue | Goserelin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level. |
Isotretinoin | Goserelin may decrease the excretion rate of Isotretinoin which could result in a higher serum level. |
Isoxicam | Isoxicam may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Isradipine | The risk or severity of QTc prolongation can be increased when Isradipine is combined with Goserelin. |
Itraconazole | The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Goserelin. |
Ivabradine | Ivabradine may increase the QTc-prolonging activities of Goserelin. |
Ivosidenib | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ivosidenib. |
Ixazomib | Goserelin may decrease the excretion rate of Ixazomib which could result in a higher serum level. |
Kanamycin | Goserelin may decrease the excretion rate of Kanamycin which could result in a higher serum level. |
Ketamine | Goserelin may decrease the excretion rate of Ketamine which could result in a higher serum level. |
Ketazolam | Goserelin may decrease the excretion rate of Ketazolam which could result in a higher serum level. |
Ketoconazole | The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Goserelin. |
Ketoprofen | Ketoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Ketorolac | Ketorolac may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Labetalol | Goserelin may decrease the excretion rate of Labetalol which could result in a higher serum level. |
Lacidipine | The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Goserelin. |
Lamivudine | Goserelin may decrease the excretion rate of Lamivudine which could result in a higher serum level. |
Lamotrigine | The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Goserelin. |
Lapatinib | The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Goserelin. |
Latamoxef | Latamoxef may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Ledipasvir | Goserelin may decrease the excretion rate of Ledipasvir which could result in a higher serum level. |
Lefamulin | Lefamulin may increase the QTc-prolonging activities of Goserelin. |
Lenalidomide | Goserelin may decrease the excretion rate of Lenalidomide which could result in a higher serum level. |
Lenvatinib | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lenvatinib. |
Lesinurad | Goserelin may decrease the excretion rate of Lesinurad which could result in a higher serum level. |
Leuprolide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Goserelin. |
Levacetylmethadol | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Levacetylmethadol. |
Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Levobupivacaine. |
Levocabastine | The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Goserelin. |
Levocarnitine | Goserelin may decrease the excretion rate of Levocarnitine which could result in a higher serum level. |
Levocetirizine | The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Goserelin. |
Levofloxacin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Levofloxacin. |
Levomenthol | The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Goserelin. |
Levomilnacipran | Goserelin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level. |
Levosalbutamol | Goserelin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level. |
Levosimendan | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Levosimendan. |
Lidocaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Lidocaine. |
Lidoflazine | The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Goserelin. |
Linagliptin | The therapeutic efficacy of Linagliptin can be decreased when used in combination with Goserelin. |
Liothyronine | Goserelin may decrease the excretion rate of Liothyronine which could result in a higher serum level. |
Liraglutide | The therapeutic efficacy of Liraglutide can be decreased when used in combination with Goserelin. |
Lisinopril | Goserelin may decrease the excretion rate of Lisinopril which could result in a higher serum level. |
Lithium carbonate | Goserelin may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. |
Lithium citrate | Lithium citrate may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Lixisenatide | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Goserelin. |
Lofexidine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lofexidine. |
Lomefloxacin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lomefloxacin. |
Loperamide | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Loperamide. |
Lopinavir | The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Goserelin. |
Loracarbef | Loracarbef may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Lorazepam | Goserelin may decrease the excretion rate of Lorazepam which could result in a higher serum level. |
Lorcaserin | Goserelin may decrease the excretion rate of Lorcaserin which could result in a higher serum level. |
Lornoxicam | Lornoxicam may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Lorpiprazole | Goserelin may decrease the excretion rate of Lorpiprazole which could result in a higher serum level. |
Losartan | The risk or severity of QTc prolongation can be increased when Losartan is combined with Goserelin. |
Loxoprofen | Loxoprofen may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Lubiprostone | Goserelin may decrease the excretion rate of Lubiprostone which could result in a higher serum level. |
Lumefantrine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Lumefantrine. |
Lumiracoxib | Lumiracoxib may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Lurasidone | The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Goserelin. |
Macimorelin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Macimorelin. |
Macitentan | Goserelin may decrease the excretion rate of Macitentan which could result in a higher serum level. |
Magnesium car | Goserelin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. |
Magnesium chl | Goserelin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level. |
Magnesium hydr | Goserelin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level. |
Magnesium trisi | Goserelin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. |
Mangafodipir | Goserelin may decrease the excretion rate of Mangafodipir which could result in a higher serum level. |
Mannitol | Mannitol may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Maprotiline | The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Goserelin. |
Mecamylamine | Goserelin may decrease the excretion rate of Mecamylamine which could result in a higher serum level. |
Mecasermin | The therapeutic efficacy of Mecasermin can be decreased when used in combination with Goserelin. |
Meclofenamic acid | Meclofenamic acid may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Medroxyprogester | Goserelin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level. |
Mefenamic acid | Mefenamic acid may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Mefloquine | The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Goserelin. |
Megestrol acetate | Goserelin may decrease the excretion rate of Megestrol acetate which could result in a higher serum level. |
Meloxicam | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Meloxicam. |
Memantine | Goserelin may decrease the excretion rate of Memantine which could result in a higher serum level. |
Meperidine | Goserelin may decrease the excretion rate of Meperidine which could result in a higher serum level. |
Mepivacaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Mepivacaine. |
Mepyramine | The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Goserelin. |
Meropenem | Goserelin may decrease the excretion rate of Meropenem which could result in a higher serum level. |
Mesalazine | Mesalazine may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Mesoridazine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mesoridazine. |
Metamfetamine | Goserelin may decrease the excretion rate of Metamfetamine which could result in a higher serum level. |
Metamizole | Metamizole may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Metaxalone | Goserelin may decrease the excretion rate of Metaxalone which could result in a higher serum level. |
Metformin | The therapeutic efficacy of Metformin can be decreased when used in combination with Goserelin. |
Methadone | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Methadone. |
Methazolamide | Methazolamide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Methimazole | Goserelin may decrease the excretion rate of Methimazole which could result in a higher serum level. |
Methotrexate | Methotrexate may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Methotrimeprazine | The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Goserelin. |
Methoxsalen | Goserelin may decrease the excretion rate of Methoxsalen which could result in a higher serum level. |
Methoxy | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Goserelin. |
Methsuximide | The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Goserelin. |
Methyldopa | Goserelin may decrease the excretion rate of Methyldopa which could result in a higher serum level. |
Methylene blue | Goserelin may decrease the excretion rate of Methylene blue which could result in a higher serum level. |
Methylnaltrexone | Goserelin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level. |
Methyltestosterone | Goserelin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level. |
Meticrane | Meticrane may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Metoclopramide | The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Goserelin. |
Metolazone | Metolazone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Metoprolol | Goserelin may decrease the excretion rate of Metoprolol which could result in a higher serum level. |
Metronidazole | The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Goserelin. |
Metyrapone | Goserelin may decrease the excretion rate of Metyrapone which could result in a higher serum level. |
Midazolam | Goserelin may decrease the excretion rate of Midazolam which could result in a higher serum level. |
Mifepristone | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mifepristone. |
Migalastat | Goserelin may decrease the excretion rate of Migalastat which could result in a higher serum level. |
Miglitol | The therapeutic efficacy of Miglitol can be decreased when used in combination with Goserelin. |
Milnacipran | Goserelin may decrease the excretion rate of Milnacipran which could result in a higher serum level. |
Milrinone | Goserelin may decrease the excretion rate of Milrinone which could result in a higher serum level. |
Mirabegron | The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Goserelin. |
Mirtazapine | The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Goserelin. |
Mizolastine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mizolastine. |
Mobocertinib | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mobocertinib. |
Moexipril | The risk or severity of QTc prolongation can be increased when Moexipril is combined with Goserelin. |
Moricizine | The risk or severity of QTc prolongation can be increased when Moricizine is combined with Goserelin. |
Moxifloxacin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Moxifloxacin. |
Moxisylyte | Goserelin may decrease the excretion rate of Moxisylyte which could result in a higher serum level. |
Muzolimine | Muzolimine may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Mycophenolate | Goserelin may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level. |
Mycophenolic acid | Goserelin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level. |
N-acetyltyrosine | Goserelin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level. |
Nabumetone | Nabumetone may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Nadolol | Goserelin may decrease the excretion rate of Nadolol which could result in a higher serum level. |
Naldemedine | Goserelin may decrease the excretion rate of Naldemedine which could result in a higher serum level. |
Nalidixic acid | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nalidixic acid. |
Nalmefene | Goserelin may decrease the excretion rate of Nalmefene which could result in a higher serum level. |
Naloxone | Goserelin may decrease the excretion rate of Naloxone which could result in a higher serum level. |
Naproxen | Naproxen may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Nateglinide | The therapeutic efficacy of Nateglinide can be decreased when used in combination with Goserelin. |
Nedaplatin | Goserelin may decrease the excretion rate of Nedaplatin which could result in a higher serum level. |
Nedocromil | Goserelin may decrease the excretion rate of Nedocromil which could result in a higher serum level. |
Nefazodone | Goserelin may decrease the excretion rate of Nefazodone which could result in a higher serum level. |
Nelfinavir | The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Goserelin. |
Neomycin | Goserelin may decrease the excretion rate of Neomycin which could result in a higher serum level. |
Netilmicin | Goserelin may decrease the excretion rate of Netilmicin which could result in a higher serum level. |
Nicardipine | The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Goserelin. |
Nicorandil | Goserelin may decrease the excretion rate of Nicorandil which could result in a higher serum level. |
Nifedipine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nifedipine. |
Nilotinib | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nilotinib. |
Nilutamide | Goserelin may decrease the excretion rate of Nilutamide which could result in a higher serum level. |
Nilvadipine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nilvadipine. |
Nimesulide | Nimesulide may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Nimodipine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Nimodipine. |
Nisoldipine | Goserelin may decrease the excretion rate of Nisoldipine which could result in a higher serum level. |
Nitrendipine | The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Goserelin. |
Nitric Oxide | Goserelin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level. |
Nitrofurantoin | Goserelin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. |
Nitroprusside | Goserelin may decrease the excretion rate of Nitroprusside which could result in a higher serum level. |
Norfloxacin | The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Goserelin. |
Nortriptyline | The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Goserelin. |
Octinoxate | Goserelin may decrease the excretion rate of Octinoxate which could result in a higher serum level. |
Octreotide | The risk or severity of QTc prolongation can be increased when Octreotide is combined with Goserelin. |
Ofloxacin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ofloxacin. |
Olanzapine | The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Goserelin. |
Olodaterol | The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Goserelin. |
Olsalazine | Olsalazine may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Ondansetron | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ondansetron. |
Opium | Goserelin may decrease the excretion rate of Opium which could result in a higher serum level. |
Orphenadrine | The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Goserelin. |
Oseltamivir | Goserelin may decrease the excretion rate of Oseltamivir which could result in a higher serum level. |
Oxacillin | Goserelin may decrease the excretion rate of Oxacillin which could result in a higher serum level. |
Oxaliplatin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Oxaliplatin. |
Oxaprozin | Oxaprozin may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Oxatomide | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Oxatomide. |
Oxazepam | Goserelin may decrease the excretion rate of Oxazepam which could result in a higher serum level. |
Oxetacaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Oxetacaine. |
Oxybenzone | Goserelin may decrease the excretion rate of Oxybenzone which could result in a higher serum level. |
Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Oxybuprocaine. |
Oxyphenbutazone | Oxyphenbutazone may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Oxyquinoline | Goserelin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. |
Oxytocin | The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Goserelin. |
Pacritinib | The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Goserelin. |
Paliperidone | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Paliperidone. |
Palonosetron | Goserelin may decrease the excretion rate of Palonosetron which could result in a higher serum level. |
Pamidronic acid | Pamidronic acid may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Panobinostat | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Panobinostat. |
Pantoprazole | Goserelin may decrease the excretion rate of Pantoprazole which could result in a higher serum level. |
Papaverine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Papaverine. |
Parecoxib | Parecoxib may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Paromomycin | Paromomycin may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Pasireotide | The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Goserelin. |
Patent Blue | Goserelin may decrease the excretion rate of Patent Blue which could result in a higher serum level. |
Pazopanib | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Pazopanib. |
Pefloxacin | The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Goserelin. |
Pegaptanib | Goserelin may decrease the excretion rate of Pegaptanib which could result in a higher serum level. |
Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Goserelin. |
Pemetrexed | Goserelin may decrease the excretion rate of Pemetrexed which could result in a higher serum level. |
Penbutolol | Goserelin may decrease the excretion rate of Penbutolol which could result in a higher serum level. |
Pentaerythritol | Goserelin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level. |
Pentamidine | The therapeutic efficacy of Pentamidine can be decreased when used in combination with Goserelin. |
Pentastarch | Goserelin may decrease the excretion rate of Pentastarch which could result in a higher serum level. |
Pentetic acid | Goserelin may decrease the excretion rate of Pentetic acid which could result in a higher serum level. |
Pentobarbital | Goserelin may decrease the excretion rate of Pentobarbital which could result in a higher serum level. |
Pentostatin | Goserelin may decrease the excretion rate of Pentostatin which could result in a higher serum level. |
Pentoxifylline | Goserelin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level. |
Perflutren | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Perflutren. |
Perhexiline | The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Goserelin. |
Perindopril | Goserelin may decrease the excretion rate of Perindopril which could result in a higher serum level. |
Permethrin | Goserelin may decrease the excretion rate of Permethrin which could result in a higher serum level. |
Phenazopyridine | Phenazopyridine may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Phenelzine | Goserelin may decrease the excretion rate of Phenelzine which could result in a higher serum level. |
Phenformin | The therapeutic efficacy of Phenformin can be decreased when used in combination with Goserelin. |
Pheniramine | The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Goserelin. |
Phenol | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Phenol. |
Phentolamine | Goserelin may decrease the excretion rate of Phentolamine which could result in a higher serum level. |
Phenylbutazone | Phenylbutazone may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Pholcodine | Goserelin may decrease the excretion rate of Pholcodine which could result in a higher serum level. |
Phosphoric acid | Goserelin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. |
Phylloquinone | Goserelin may decrease the excretion rate of Phylloquinone which could result in a higher serum level. |
Picosulfuric acid | Goserelin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level. |
Pimozide | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Pimozide. |
Pinaverium | The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Goserelin. |
Pindolol | Goserelin may decrease the excretion rate of Pindolol which could result in a higher serum level. |
Pioglitazone | The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Goserelin. |
Piperacillin | Goserelin may decrease the excretion rate of Piperacillin which could result in a higher serum level. |
Piracetam | Goserelin may decrease the excretion rate of Piracetam which could result in a higher serum level. |
Piretanide | Piretanide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Piroxicam | Piroxicam may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Pitolisant | Goserelin may increase the QTc-prolonging activities of Pitolisant. |
Plazomicin | Goserelin may decrease the excretion rate of Plazomicin which could result in a higher serum level. |
Plerixafor | Goserelin may decrease the excretion rate of Plerixafor which could result in a higher serum level. |
Polythiazide | Polythiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Pomalidomide | Goserelin may decrease the excretion rate of Pomalidomide which could result in a higher serum level. |
Ponesimod | The risk or severity of bradycardia can be increased when Ponesimod is combined with Goserelin. |
Posaconazole | The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Goserelin. |
Potassium | Potassium may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Potassium acetate | Goserelin may decrease the excretion rate of Potassium acetate which could result in a higher serum level. |
Potassium | Goserelin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level. |
Potassium cation | Potassium cation may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Potassium chloride | Goserelin may decrease the excretion rate of Potassium chloride which could result in a higher serum level. |
Potassium citrate | Potassium citrate may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Potassium nitrate | Goserelin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level. |
Potassium | Goserelin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level. |
Potassium sulfate | Goserelin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level. |
Pralatrexate | Goserelin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. |
Pralidoxime | Goserelin may decrease the excretion rate of Pralidoxime which could result in a higher serum level. |
Pramipexole | Goserelin may decrease the excretion rate of Pramipexole which could result in a higher serum level. |
Pramlintide | The therapeutic efficacy of Pramlintide can be decreased when used in combination with Goserelin. |
Pramocaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Pramocaine. |
Prasugrel | Goserelin may decrease the excretion rate of Prasugrel which could result in a higher serum level. |
Prednisone | Goserelin may decrease the excretion rate of Prednisone which could result in a higher serum level. |
Pregabalin | The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Goserelin. |
Prenylamine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Prenylamine. |
Prilocaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Prilocaine. |
Primaquine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Primaquine. |
Probenecid | Goserelin may decrease the excretion rate of Probenecid which could result in a higher serum level. |
Probucol | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Probucol. |
Procainamide | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Procainamide. |
Procaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Procaine. |
Procaine benz | Goserelin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. |
Prochlorperazine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Prochlorperazine. |
Promazine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Promazine. |
Promethazine | The risk or severity of QTc prolongation can be increased when Promethazine is combined with Goserelin. |
Propafenone | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Propafenone. |
Propantheline | Goserelin may decrease the excretion rate of Propantheline which could result in a higher serum level. |
Proparacaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Proparacaine. |
Propiverine | Goserelin may decrease the excretion rate of Propiverine which could result in a higher serum level. |
Propofol | The risk or severity of QTc prolongation can be increased when Propofol is combined with Goserelin. |
Propoxycaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Propoxycaine. |
Propranolol | Goserelin may decrease the excretion rate of Propranolol which could result in a higher serum level. |
Protriptyline | The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Goserelin. |
Prucalopride | Goserelin may decrease the excretion rate of Prucalopride which could result in a higher serum level. |
Pyrantel | Goserelin may decrease the excretion rate of Pyrantel which could result in a higher serum level. |
Pyrazinamide | Goserelin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level. |
Pyridoxine | Goserelin may decrease the excretion rate of Pyridoxine which could result in a higher serum level. |
Pyrithione | Goserelin may decrease the excretion rate of Pyrithione which could result in a higher serum level. |
Quetiapine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Quetiapine. |
Quinethazone | Quinethazone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Quinidine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Quinidine. |
Quinine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Quinine. |
Rabeprazole | Goserelin may decrease the excretion rate of Rabeprazole which could result in a higher serum level. |
Ramelteon | Goserelin may decrease the excretion rate of Ramelteon which could result in a higher serum level. |
Ranitidine | Goserelin may decrease the excretion rate of Ranitidine which could result in a higher serum level. |
Ranolazine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ranolazine. |
Rasagiline | Goserelin may decrease the excretion rate of Rasagiline which could result in a higher serum level. |
Relugolix | The risk or severity of QTc prolongation can be increased when Relugolix is combined with Goserelin. |
Repaglinide | The therapeutic efficacy of Repaglinide can be decreased when used in combination with Goserelin. |
Reserpine | Goserelin may decrease the excretion rate of Reserpine which could result in a higher serum level. |
Resorcinol | Goserelin may decrease the excretion rate of Resorcinol which could result in a higher serum level. |
Ribavirin | Goserelin may decrease the excretion rate of Ribavirin which could result in a higher serum level. |
Ribociclib | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Ribociclib. |
Ribostamycin | Goserelin may decrease the excretion rate of Ribostamycin which could result in a higher serum level. |
Rilpivirine | The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Goserelin. |
Risperidone | The risk or severity of QTc prolongation can be increased when Risperidone is combined with Goserelin. |
Ritonavir | The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Goserelin. |
Rivaroxaban | Goserelin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. |
Rizatriptan | Goserelin may decrease the excretion rate of Rizatriptan which could result in a higher serum level. |
Rofecoxib | Rofecoxib may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Roflumilast | Goserelin may decrease the excretion rate of Roflumilast which could result in a higher serum level. |
Romidepsin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Romidepsin. |
Ropivacaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Ropivacaine. |
Rosiglitazone | The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Goserelin. |
Rosoxacin | The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Goserelin. |
Roxithromycin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Roxithromycin. |
Rupatadine | The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Goserelin. |
Ruxolitinib | Goserelin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level. |
Sacubitril | Goserelin may decrease the excretion rate of Sacubitril which could result in a higher serum level. |
Salbutamol | The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Goserelin. |
Salicylamide | Salicylamide may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Salicylic acid | Salicylic acid may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Salmeterol | The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Goserelin. |
Salmon calcitonin | Goserelin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level. |
Salsalate | Salsalate may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Saquinavir | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Saquinavir. |
Saxagliptin | The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Goserelin. |
Secobarbital | Goserelin may decrease the excretion rate of Secobarbital which could result in a higher serum level. |
Selenious acid | Goserelin may decrease the excretion rate of Selenious acid which could result in a higher serum level. |
Selenium | Goserelin may decrease the excretion rate of Selenium which could result in a higher serum level. |
Semaglutide | The therapeutic efficacy of Semaglutide can be decreased when used in combination with Goserelin. |
Sevoflurane | The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Goserelin. |
Sibutramine | Goserelin may decrease the excretion rate of Sibutramine which could result in a higher serum level. |
Sitagliptin | The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Goserelin. |
Sodium acetate | Goserelin may decrease the excretion rate of Sodium acetate which could result in a higher serum level. |
Sodium auro | Goserelin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level. |
Sodium fluoride | Goserelin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level. |
Sodium sulfate | Goserelin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. |
Sofosbuvir | Goserelin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. |
Solifenacin | The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Goserelin. |
Solriamfetol | Goserelin may decrease the excretion rate of Solriamfetol which could result in a higher serum level. |
Sorafenib | The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Goserelin. |
Sorbitol | Goserelin may decrease the excretion rate of Sorbitol which could result in a higher serum level. |
Sotagliflozin | The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Goserelin. |
Sotalol | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sotalol. |
Sparfloxacin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sparfloxacin. |
Spironolactone | Spironolactone may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Stiripentol | Goserelin may decrease the excretion rate of Stiripentol which could result in a higher serum level. |
Streptomycin | Goserelin may decrease the excretion rate of Streptomycin which could result in a higher serum level. |
Strontium chloride | Goserelin may decrease the excretion rate of Strontium chloride which could result in a higher serum level. |
Sucralfate | Goserelin may decrease the excretion rate of Sucralfate which could result in a higher serum level. |
Sulbactam | Goserelin may decrease the excretion rate of Sulbactam which could result in a higher serum level. |
Sulfadiazine | The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Goserelin. |
Sulfamethoxazole | The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Goserelin. |
Sulfasalazine | Sulfasalazine may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Sulfisoxazole | The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Goserelin. |
Sulindac | Sulindac may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Sulpiride | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sulpiride. |
Sultopride | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sultopride. |
Sumatriptan | Goserelin may decrease the excretion rate of Sumatriptan which could result in a higher serum level. |
Sunitinib | The therapeutic efficacy of Sunitinib can be decreased when used in combination with Goserelin. |
Tacrolimus | The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Goserelin. |
Tadalafil | Goserelin may decrease the excretion rate of Tadalafil which could result in a higher serum level. |
Tamoxifen | The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Goserelin. |
Tamsulosin | Goserelin may decrease the excretion rate of Tamsulosin which could result in a higher serum level. |
Tasimelteon | Goserelin may decrease the excretion rate of Tasimelteon which could result in a higher serum level. |
Technetium T | Goserelin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level. |
Technetium | Goserelin may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level. |
Technetium | Goserelin may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level. |
Technetium Tc | Goserelin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. |
Teduglutide | Goserelin may decrease the excretion rate of Teduglutide which could result in a higher serum level. |
Tegafur | Goserelin may decrease the excretion rate of Tegafur which could result in a higher serum level. |
Telavancin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Telavancin. |
Telithromycin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Telithromycin. |
Temazepam | Goserelin may decrease the excretion rate of Temazepam which could result in a higher serum level. |
Temozolomide | Goserelin may decrease the excretion rate of Temozolomide which could result in a higher serum level. |
Tenofovir | The serum concentration of Tenofovir alafenamide can be increased when it is combined with Goserelin. |
Tenofovir | Tenofovir disoproxil may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Tenoxicam | Tenoxicam may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Terbutaline | The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Goserelin. |
Terfenadine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Terfenadine. |
Terlipressin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Terlipressin. |
Testolactone | Goserelin may decrease the excretion rate of Testolactone which could result in a higher serum level. |
Testosterone | Goserelin may decrease the excretion rate of Testosterone which could result in a higher serum level. |
Testosterone | Goserelin may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. |
Testosterone | Goserelin may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. |
Testosterone pro | Goserelin may decrease the excretion rate of Testosterone propionate which could result in a higher serum level. |
Testosterone undec | Goserelin may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level. |
Tetrabenazine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Tetrabenazine. |
Tetracaine | The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Tetracaine. |
Tetracycline | Goserelin may decrease the excretion rate of Tetracycline which could result in a higher serum level. |
Tetradecyl | Goserelin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level. |
Thiabendazole | Goserelin may decrease the excretion rate of Thiabendazole which could result in a higher serum level. |
Thiethylperazine | Goserelin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level. |
Thioridazine | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Thioridazine. |
Thiothixene | The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Goserelin. |
Tiaprofenic acid | Tiaprofenic acid may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Ticlopidine | Goserelin may decrease the excretion rate of Ticlopidine which could result in a higher serum level. |
Tiludronic acid | Goserelin may decrease the excretion rate of Tiludronic acid which could result in a higher serum level. |
Timolol | The risk or severity of QTc prolongation can be increased when Timolol is combined with Goserelin. |
Tinidazole | Goserelin may decrease the excretion rate of Tinidazole which could result in a higher serum level. |
Tiopronin | Goserelin may decrease the excretion rate of Tiopronin which could result in a higher serum level. |
Tiotropium | Goserelin may decrease the excretion rate of Tiotropium which could result in a higher serum level. |
Tirofiban | Goserelin may decrease the excretion rate of Tirofiban which could result in a higher serum level. |
Tirzepatide | The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Goserelin. |
Tixocortol | Goserelin may decrease the excretion rate of Tixocortol which could result in a higher serum level. |
Tizanidine | The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Goserelin. |
Tobramycin | Goserelin may decrease the excretion rate of Tobramycin which could result in a higher serum level. |
Tocopherol | Goserelin may decrease the excretion rate of Tocopherol which could result in a higher serum level. |
Tolazamide | The therapeutic efficacy of Tolazamide can be decreased when used in combination with Goserelin. |
Tolbutamide | The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Goserelin. |
Tolcapone | Goserelin may decrease the excretion rate of Tolcapone which could result in a higher serum level. |
Tolfenamic acid | Tolfenamic acid may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Tolmetin | Tolmetin may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Tolterodine | The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Goserelin. |
Tolvaptan | Tolvaptan may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Topiramate | Goserelin may decrease the excretion rate of Topiramate which could result in a higher serum level. |
Topotecan | Goserelin may decrease the excretion rate of Topotecan which could result in a higher serum level. |
Torasemide | Torasemide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Toremifene | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Toremifene. |
Tositumomab | Goserelin may decrease the excretion rate of Tositumomab which could result in a higher serum level. |
Tramadol | Goserelin may decrease the excretion rate of Tramadol which could result in a higher serum level. |
Trametinib | Goserelin may decrease the excretion rate of Trametinib which could result in a higher serum level. |
Trazodone | The risk or severity of QTc prolongation can be increased when Trazodone is combined with Goserelin. |
Treprostinil | The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Goserelin. |
Triamterene | Triamterene may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Triazolam | Goserelin may decrease the excretion rate of Triazolam which could result in a higher serum level. |
Trichlormethiazide | Trichlormethiazide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
Triclabendazole | The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Goserelin. |
Triethylenetetram | Goserelin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level. |
Trifluridine | Goserelin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
Trimebutine | The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Goserelin. |
Trimethadione | The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Goserelin. |
Trimethoprim | Goserelin may decrease the excretion rate of Trimethoprim which could result in a higher serum level. |
Trimetrexate | Goserelin may decrease the excretion rate of Trimetrexate which could result in a higher serum level. |
Trimipramine | The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Goserelin. |
Triprolidine | The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Goserelin. |
Triptorelin | The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Goserelin. |
Troglitazone | The therapeutic efficacy of Troglitazone can be decreased when used in combination with Goserelin. |
Tropisetron | Goserelin may decrease the excretion rate of Tropisetron which could result in a higher serum level. |
Trovafloxacin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Trovafloxacin. |
Vaborbactam | Goserelin may decrease the excretion rate of Vaborbactam which could result in a higher serum level. |
Valaciclovir | Valaciclovir may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Valbenazine | Goserelin may decrease the excretion rate of Valbenazine which could result in a higher serum level. |
Valdecoxib | Valdecoxib may decrease the excretion rate of Goserelin which could result in a higher serum level. |
Valganciclovir | Goserelin may decrease the excretion rate of Valganciclovir which could result in a higher serum level. |
Valproic acid | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Valproic acid. |
Vancomycin | Goserelin may decrease the excretion rate of Vancomycin which could result in a higher serum level. |
Vandetanib | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Vandetanib. |
Vardenafil | The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Goserelin. |
Varenicline | Goserelin may decrease the excretion rate of Varenicline which could result in a higher serum level. |
Vemurafenib | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Vemurafenib. |
Venlafaxine | Goserelin may decrease the excretion rate of Venlafaxine which could result in a higher serum level. |
Verapamil | Goserelin may decrease the excretion rate of Verapamil which could result in a higher serum level. |
Vernakalant | The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Goserelin. |
Vilanterol | The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Goserelin. |
Vildagliptin | The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Goserelin. |
Viloxazine | Goserelin may decrease the excretion rate of Viloxazine which could result in a higher serum level. |
Voriconazole | The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Goserelin. |
Vorinostat | The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Goserelin. |
Vortioxetine | Goserelin may decrease the excretion rate of Vortioxetine which could result in a higher serum level. |
Pregnancy and Lactation
AU TGA pregnancy category: D
US FDA pregnancy category:
Pregnancy
This drug is contraindicated during pregnancy unless it is being used for the palliative treatment of advanced breast cancer. This drug can harm a developing fetus. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. There is an increased risk of pregnancy loss due to hormone changes caused by this drug. Verify negative pregnancy status in females of reproductive potential prior to initiating therapy.
Lactation
A decision should be made to either discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother; some experts consider use to be contraindicated.
How should this medicine be used?
Goserelin comes as an implant to be inserted with a syringe subcutaneously (under the skin) in your stomach area by a doctor or nurse in a medical office or clinic. An implant with 3.6 mg of goserelin is usually inserted every 4 weeks. An implant with 10.8 mg of goserelin is usually inserted every 12 weeks. The length of your treatment depends on the condition being treated and your response to the medication. Your doctor will determine how long you should use the goserelin implant.
Goserelin may cause an increase in certain hormones in the first few weeks after insertion of the implant. Your doctor will monitor you carefully for any new or worsening symptoms during this time.
What special precautions should I follow?
Before receiving a goserelin implant,
- tell your doctor and pharmacist if you are allergic to goserelin, histrelin (Supprelin LA, Vantas), leuprolide (Eligard, Lupron), nafarelin (Synarel), triptorelin (Trelstar), any other medications, or any of the ingredients in goserelin implant. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: medications for seizures or oral steroids such as dexamethasone (Decadron, Dexpak), methylprednisolone (Medrol), and prednisone (Sterapred). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor if you have a history of drinking alcohol or using tobacco products for a long period of time, or if you or anyone in your family has or has ever had osteoporosis (a condition in which the bones become thin and weak and break easily), or if you have or have ever had a compressed spinal cord, diabetes, unusual vaginal bleeding, urinary obstruction in men (blockage that causes difficulty urinating), or heart or liver disease.
- tell your doctor if you are pregnant or plan to become pregnant. Goserelin implants should not be used in pregnant women, except for the treatment of advanced breast cancer. Call your doctor right away if you think you have become pregnant during your treatment. Goserelin implant may harm the fetus. You should not plan to become pregnant while using a goserelin implant or for 12 weeks after your treatment. Your doctor may perform a pregnancy test or tell you to begin your treatment during your menstrual period to be sure that you are not pregnant when you begin using the goserelin implant. You will need to use a reliable nonhormonal method of birth control to prevent pregnancy while you are using a goserelin implant and for 12 weeks after your treatment. Talk to your doctor about the types of birth control that are right for you, and continue to use birth control even though you should not have regular menstrual periods during your treatment. tell your doctor if you are breastfeeding. You should not breastfeed during your treatment with a goserelin implant.
References